查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1840628

動物用藥品市場按產品類型、動物類型、給藥途徑、適應症、分銷管道和最終用戶分類－2025-2032年全球預測

Veterinary Pharmaceuticals Market by Products, Animal Type, Mode of Administration, Indications, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，動物用藥品市場規模將達到 784.3 億美元，年複合成長率為 8.60%。

主要市場統計數據
基準年 2024 405.3億美元
預計年份：2025年 438.8億美元
預測年份：2032年 784.3億美元
複合年成長率 (%) 8.60%

臨床創新、監管壓力和相關人員優先事項的綜合框架重新定義了動物用藥品的戰略要務。

動物用藥品產業正處於一個關鍵的十字路口，科學進步、不斷發展的動物照護模式以及日益嚴格的監管正在匯聚，重新定義產品的研發、分銷和應用方式。本出版物綜合分析了影響包括製造商、獸醫、動物保健網路和終端用戶在內的相關人員優先事項的關鍵因素。它著重闡述了治療方法創新、抗菌藥物管理和商業性動態之間的相互作用，以及這些因素如何影響整個價值鏈的決策，從而組裝了更廣泛的背景框架。

包括精準抗寄生蟲藥物、先進的疫苗平台以及專為伴侶動物用藥設計的製劑在內的新型治療方法，正在挑戰傳統的產品系列和運作模式。同時，支付方和採購管道要求提供更清晰的臨床價值和安全性證據，監管機構也加強了對殘留物和風險緩解措施的監測。這些壓力既帶來了限制，也帶來了機會。專注於標靶適應症開發、改善給藥系統和整合服務的公司，最能滿足不斷變化的臨床需求。此次招聘將著重於了解技術進步和政策變化如何相互作用，從而為行業參與者創造近期戰略要務。

生物技術、數位診斷和監管舉措領域的策略格局正在發生變化，這正在重塑研發、分銷和投資重點。

一系列橫跨實驗室、農場和診所的變革正在改變這一切。生物技術驅動的疫苗和新型抗菌藥物正在重塑治療管道，而數位健康工具和遠端醫療正日益影響伴侶動物和牲畜的治療行為和依從性。這些技術進步縮短了診斷時間，實現了更精準的干涉，改變了對傳統頻譜藥物的需求模式，並將投資轉向了標靶性強、循證的產品。

同時，監管機構和社會對抗生素合理使用的日益重視，正在加速推廣含藥飼料替代品、生技藥品和預防策略，促使生產商重新思考其產品線並重新評估其生命週期策略。隨著線上藥局和綜合獸醫服務的日益普及，市場參與企業也正在應對不斷變化的採購管道，這些管道推動了新的分銷和商業化模式的出現。金融機構和策略夥伴優先考慮那些展現出強大的資料整合能力、可擴展的生產能力和敏捷的供應鏈管理能力的公司。總而言之，最顯著的變化包括技術成熟度的提高、監管力度的加強、通路的演變以及投資者對數據主導、可擴展資產組合的偏好。

2025年關稅調整將如何改變動物用藥品價值鏈的籌資策略、供應鏈在地化和貿易條款？

2025年實施的關稅調整的累積影響正在加劇整個動物用藥品生態系統在成本、供應鏈和策略採購方面的考慮。製造商和經銷商正在重新調整籌資策略，以減輕關稅相關的成本上漲，同時確保能夠從全球供應商獲得關鍵的活性藥物原料藥、輔料和特殊包裝材料。這種調整促使他們更加重視供應商多元化、將關鍵生產流程外包以及重新談判貿易條款，以在不影響品質或合規性的前提下維持利潤率穩定。

這些金融逆風也影響下游相關人員，包括獸醫診所和畜牧場，迫使他們最佳化庫存並優先考慮高價值干預措施。為此，企業正在加快對本地製造夥伴關係以及能夠提供不受關稅影響的供應鏈的合約開發和受託製造廠商的投資。同時，長期策略應對措施包括重新設計產品系列，以減少對關稅敏感型投入的依賴，並加強與區域合作夥伴的協作，以簡化海關程序和合規文件。這些措施的共同實施將減輕未來貿易衝擊的影響，並確保伴侶動物和牲畜能夠持續獲得治療。

透過對產品、動物類型、給藥方式、適應症、管道和最終用戶進行綜合細分分析，提供有針對性的開發和商業化策略。

有效的市場區隔能夠識別價值創造與臨床需求的交集，從而指導產品策略和通路部署。按產品類型分類，市場包括藥品、藥用飼料和疫苗。藥品再細分為止痛藥、抗感染藥、抗發炎藥和抗寄生蟲藥等次類別。抗感染藥進一步分為抗生素和抗真菌藥物，抗發炎藥分為非類固醇類抗發炎藥和類固醇類抗發炎藥，抗寄生蟲藥分為體外寄生蟲藥和體內寄生蟲藥。藥用飼料涵蓋抗生素藥用飼料、抗寄生蟲藥用飼料、生長促進劑、營養藥用飼料以及益生菌和益生元藥用飼料。疫苗細分則根據平台和風險等級進行，區分去活化疫苗和活病毒疫苗疫苗，並重點闡述每種疫苗的低溫運輸和監管要求。

伴侶動物分為貓、狗和馬，而家畜則分為牛、雞、羊、山羊和豬。每種動物都有其獨特的治療需求和給藥方式。給藥途徑進一步影響製劑策略，注射劑包括肌肉注射和皮下注射；口服劑型包括膠囊、液體混懸劑、糖漿和錠劑；外用劑型包括乳膏、洗劑和軟膏。按適應症細分可以突出關鍵領域，例如慢性疼痛和急性疼痛管理、免疫系統疾病、感染疾病、代謝和神經系統疾病、整形外科疾病、寄生蟲感染疾病和生殖健康，從而指導臨床證據的生成和標籤聲明。分銷管道涵蓋線上藥局、零售藥局和獸醫診所，每種通路的購買行為和監管要求各不相同。最終用戶，包括養殖場、寵物飼主和獸醫診所，會影響定價、包裝和支援服務。整合這些細分層可以更精確地針對研發投資、商業化計畫和上市後監測策略。

美洲、歐洲、中東和非洲以及亞太地區的區域動態和監管差異將決定市場准入、應用和供應鏈策略。

區域動態對不同地區的法律規範、供應鏈韌性和商業機會的影響各不相同。在美洲，市場活躍度主要受以下因素驅動：伴侶動物對先進療法的高接受度、不斷進步的獸醫實踐標準，以及強大的零售和診所分銷網路，這些因素加速了新型配方的推廣。不同地區的貿易行為和報銷機制存在差異，促使製造商調整定價策略，並強調產品安全性和便利性，以滿足寵物飼主和大型農場的需求。

歐洲、中東和非洲的法規環境既嚴格又成熟度參差不齊。中東和非洲市場既蘊藏成長機遇，也面臨物流的挑戰，例如低溫運輸基礎設施的差異和進口法規的不同。亞太地區的特點是畜牧業快速現代化，對預防性疫苗和藥用飼料的需求不斷成長，以及在先進療法投資增加的推動下，伴侶動物市場也在蓬勃發展。供應鏈考量和本地製造夥伴關係在每個地區都發揮著至關重要的作用，而監管協調工作（如有）將對打入市場策略和產品生命週期管理產生重大影響。

透過整合研發、卓越製造和策略夥伴關係，實現競爭優勢差異化，加速生技藥品和先進療法的商業化進程。

該領域的競爭格局呈現出大型跨國公司、專業生物技術公司和靈活高效的契約製造並存的態勢。主要企業憑藉其整合能力脫穎而出，將研發實力、先進的生產能力和廣泛的商業網路相結合，從而實現生技藥品和複雜製劑的快速規模化生產。策略聯盟和授權協議十分常見，企業希望藉助利基技術供應商來補充自身內部的專業知識，尤其是在疫苗平台開發和新型抗寄生蟲藥物領域。

創新資金籌措正日益透過有針對性的夥伴關係來推動，大型企業提供資金和商業化路徑，而小型企業則提供科學創新。投資於依從性監測、遠端醫療輔助配藥以及數據主導的藥物安全檢測數位化工具的公司，能夠加強與獸醫和動物飼主的關係。低溫運輸物流、法規事務和生產品質的卓越營運是持久的差異化優勢，能夠提供強而有力的臨床證據和管理框架也同樣重要。總而言之，競爭格局有利於那些將科學創新與嚴謹的商業化和供應鏈韌性結合的公司。

採取切實可行的策略行動，協調研發、供應鏈韌性、管理和數位化商業化，以實現永續的競爭優勢。

為了充分發揮臨床和商業性價值，產業領導者應圍繞兩大要務調整策略：創新和供應鏈韌性。優先發展標靶治療和預防性生技藥品，同時將抗菌藥物管理納入標籤、行銷和上市後監測活動，以滿足監管機構和社會期望。投資於能夠提高患者依從性、減少給藥頻率和簡化給藥方式的製劑技術，將獲得臨床醫生和製劑所有者的支持。

同時，我們將調整籌資策略，降低關稅風險，並透過多元化的供應商網路和區域製造夥伴關係冗餘體系。我們將整合數位互動平台與傳統分銷管道，強化商業化進程，以支援遠端醫療工作流程、依從性監測和資料收集，從而增強真實世界證據的生成。我們將探索合作研究和授權模式，加速新型平台的普及，同時實施嚴格的藥物安全檢測和品質體系，以維護相關人員的信任。最後，我們將根據當地法規環境和特定物種的需求調整市場推廣計劃，確保我們的臨床價值提案與當地實踐模式相符。

結合主要相關人員訪談、科學文獻綜述、監管分析和供應鏈圖譜的穩健混合調查方法，確保了可操作的洞見。

本分析採用嚴謹的調查方法，結合多面向分析，並將主要相關人員的見解與二手科學和監管文獻進行三角驗證。主要研究包括對獸醫、行業高管、生產合作夥伴和分銷管道負責人進行結構化訪談，以了解營運現狀、未滿足的臨床需求和採購動態。這些定性資訊與官方監管文件、專家科學研究和公司揭露資訊相結合，用於檢驗治療趨勢並評估政策變化帶來的實際影響。

分析步驟包括按產品類型、物種、給藥途徑、適應症、分銷管道和最終用戶進行細分映射，以便對臨床需求與商業機會之間的匹配度進行細緻解讀。供應鏈分析著重於採購風險、關稅影響和生產能力限制。最後，競爭評估優先考慮研發、生產、法規事務和數位化互動方面的能力。在整個調查方法中，我們確保假設的透明度，並透過多個獨立資訊來源驗證研究結果，以增強結論和建議的可信度。

總結報告強調了創新協同、整合管理和供應鏈重組對於將科學進步轉化為永續商業性成果的重要性。

總之，在生技藥品和標靶治療的技術創新、不斷變化的監管預期以及貿易調整和動態帶來的商業性壓力等因素的共同推動下，動物用藥品行業正經歷著劇烈的變革。這些因素迫使企業在產品設計、證據產生和供應鏈配置方面採取更具策略性的策略。積極實踐管理原則、投資合規產品配方並建立抗關稅採購管道的企業，將更有能力滿足臨床醫生和寵物主人的期望，同時保持營運利潤率。

這些措施包括加速研發疫苗和標靶抗寄生蟲藥物，以減少對廣譜抗生素的依賴；實現生產和物流現代化，以減輕貿易中斷的影響；以及應用數位化工具來提升臨床決策和用藥依從性。透過將創新重點與當地監管細則和終端用戶行為相結合，企業可以將科學進步轉化為永續的商業性成果，並改善動物健康。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 更嚴格的監管促進了牲畜飼料中非抗生素生長促進劑的研發。
  • 整合虛擬諮詢和電子配藥等功能的遠距遠端醫療平台在寵物護理領域蓬勃發展
  • 採用單株抗體和新型生技藥品標靶治療犬貓疾病
  • 獸醫護理中緩釋性注射劑等先進藥物傳輸系統的推廣應用
  • 將穿戴式健康監測技術與藥物治療結合，以提高治療順從性
  • 擴大植物來源營養補充品和功能性寵物食品的市場，以促進獸醫健康預防

第6章美國關稅的累積影響，2025年

第7章 人工智慧的累積影響，2025年

第8章動物用藥品市場產品分類

  • 藥物
    • 止痛藥
    • 抗感染藥物
      • 抗生素
      • 抗真菌藥物
    • 抗發炎藥
      • 非類固醇類
      • 類固醇
    • 殺寄生蟲劑
      • 體外寄生蟲殺滅劑
      • 體內殺寄生蟲劑
  • 藥用飼料
    • 含抗生素的藥用飼料
    • 驅蟲飼料
    • 生長促進劑
    • 營養和藥用飼料
    • 益生菌和益生元處方藥用飼料
  • 疫苗
    • 去活化疫苗
    • 活病毒疫苗

第9章 依動物類型分類的動物用藥品市場

  • 伴侶動物
    • 貓
    • 狗
    • 馬
  • 家畜
    • 牛
    • 家禽
    • 綿羊和山羊
    • 豬

第10章 依給藥途徑分類的動物用藥品市場

  • 注射
    • 肌肉內注射
    • 皮下
  • 口服
    • 膠囊
    • 液體懸浮液和糖漿
    • 藥片
  • 局部的
    • 奶油
    • 洗劑
    • 軟膏

第11章動物用藥品

  • 慢性疼痛和急性疼痛管理
  • 免疫狀態
  • 感染疾病
  • 代謝紊亂
  • 神經系統疾病
  • 整形外科疾病
  • 寄生蟲感染疾病
  • 生殖健康

第12章 按分銷管道分類的動物用藥品市場

  • 網路藥房
  • 零售藥房
  • 獸醫診所

第13章 依最終用戶分類的動物用藥品市場

  • 動物農場
  • 寵物飼主
  • 獸醫診所

第14章 按地區分類的動物用藥品市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章動物用藥品市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國動物用藥品市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Aurora Pharmaceutical, Inc.
    • Biogenesis Bago SA
    • Biovac Ltd.
    • Boehringer Ingelheim International GmbH
    • Ceva Sante Animale
    • Chanelle Pharma
    • China Animal Husbandry Industry Co., Ltd.
    • Dechra Pharmaceuticals PLC
    • ECO Animal Health Group PLC
    • Elanco Animal Health Incorporated
    • Heska Corporation
    • Hester Biosciences Limited
    • Indian Immunologicals Ltd.
    • Intas Pharmaceuticals Ltd.
    • Laboratorio Drag Pharma Chile Invetec SA
    • Merck & Co., Inc.
    • Neogen Corporation
    • Norbrook Group
    • Phibro Animal Health Corporation
    • Teknofarma Srl
    • Vetoquinol Group
    • Vetpharma Animal Health SL by Insud Pharma SLU
    • Virbac SA
    • Zendal Group
    • Zoetis Inc.
Product Code: MRR-032F197B035E

The Veterinary Pharmaceuticals Market is projected to grow by USD 78.43 billion at a CAGR of 8.60% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 40.53 billion
Estimated Year [2025] USD 43.88 billion
Forecast Year [2032] USD 78.43 billion
CAGR (%) 8.60%

Comprehensive framing of clinical innovation, regulatory pressures, and stakeholder priorities that together redefine strategic imperatives in veterinary pharmaceuticals

The veterinary pharmaceuticals sector stands at a pivotal juncture where scientific progress, evolving animal care paradigms, and heightened regulatory scrutiny converge to redefine how products are developed, distributed, and deployed. This introduction synthesizes the critical forces that are shaping stakeholder priorities across manufacturers, veterinarians, animal health networks, and end users. It frames the broader context by emphasizing the interplay between therapeutic innovation, antimicrobial stewardship, and commercial dynamics that influence decision-making across the value chain.

Emerging therapeutic modalities, such as precision antiparasitics, refined vaccine platforms, and formulations tailored to compliance in companion animals, are challenging legacy product portfolios and operational models. Concurrently, payers and procurement channels are demanding clearer evidence of clinical value and safety, while regulatory authorities are tightening oversight on residues and risk mitigation. These pressures are creating both constraints and opportunities: companies focused on targeted indication development, improved delivery systems, and integrated services are best positioned to meet shifting clinical expectations. Throughout this introduction, the emphasis remains on understanding how technological advances and policy shifts interact to create near-term strategic imperatives for industry participants.

Strategic landscape shifts driven by biotechnology, digital diagnostics, and stewardship policies that are reconfiguring development, distribution, and investment priorities

The landscape is being transformed by a suite of converging shifts that extend from the laboratory to the farm and the clinic. Biotechnology-enabled vaccines and novel antimicrobial alternatives are reshaping therapeutic pathways, while digital health tools and telemedicine increasingly influence prescribing behavior and adherence across companion and livestock populations. These technological advances reduce time to diagnosis and enable more precise interventions, thereby altering demand patterns for traditional broad-spectrum drugs and shifting investment toward targeted, evidence-backed products.

At the same time, regulatory and societal emphasis on antimicrobial stewardship is accelerating the adoption of medicated-feed alternatives, biologics, and preventive strategies, prompting manufacturers to reformulate pipelines and revisit lifecycle strategies. Market participants are also contending with evolving procurement channels as online pharmacies and integrated veterinary services gain traction, driving new distribution and commercialization models. Financial sponsors and strategic partners are prioritizing companies that demonstrate robust data packages, scalable manufacturing, and agility in supply chain management. In sum, the most consequential shifts are technological maturation, regulatory tightening, channel evolution, and investor preference for data-driven, scalable asset portfolios.

How 2025 tariff adjustments are reshaping sourcing strategies, supply chain localization, and commercial terms across the veterinary pharmaceuticals value chain

The cumulative impact of tariff adjustments introduced in 2025 has amplified cost, supply chain, and strategic sourcing considerations across the veterinary pharmaceuticals ecosystem. Manufacturers and distributors are recalibrating procurement strategies to mitigate tariff-related cost inflation while preserving access to critical active pharmaceutical ingredients, excipients, and specialized packaging sourced from global suppliers. This recalibration is prompting a renewed emphasis on supplier diversification, nearshoring of critical manufacturing steps, and renegotiation of commercial terms to maintain margin stability without compromising quality or regulatory compliance.

These fiscal headwinds also affect downstream stakeholders, including veterinary clinics and animal farms, which face pressure to optimize inventory and prioritize high-value interventions. In response, companies are accelerating investments in local manufacturing partnerships and contract development and manufacturing organizations that can offer tariff-resilient supply chains. Simultaneously, longer-term strategic responses include redesigning product portfolios to reduce reliance on tariff-exposed inputs and increasing collaboration with regional partners to streamline customs processes and compliance documentation. Collectively, these measures reduce exposure to future trade shocks and support continuity of therapeutic availability for both companion animals and livestock populations.

Integrated segmentation analysis across products, species, administration modes, indications, channels, and end users to inform targeted development and commercialization strategies

Effective segmentation reveals where value creation and clinical need intersect, informing product strategy and channel deployment. When examined by product, the market encompasses Drugs, Medicinal Feed, and Vaccines. Within Drugs, subcategories include Analgesics, Anti-Infectives, Anti-Inflammatories, and Parasiticides, and the anti-infective category further differentiates into Antibiotics and Antifungals while anti-inflammatory therapies separate into Non-Steroidal and Steroidal approaches; parasiticide treatments divide into Ectoparasiticides and Endoparasiticides. Medicinal Feed covers antibiotic medicated feed, antiparasitic medicated feed, growth promoters, nutritional medicated feed, and probiotic and prebiotic medicated feed. Vaccine segmentation is driven by platform and risk profile, distinguishing between inactivated vaccines and live vaccines, each with distinct cold-chain and regulatory implications.

Segmenting by animal type clarifies demand drivers and regulatory pathways, with Companion Animals split into Cats, Dogs, and Horses and Livestock Animals encompassing Cattle, Poultry, Sheep and Goats, and Swine, each species presenting unique therapeutic needs and administration practices. Mode of administration further influences formulation strategy, where Injectable routes include intramuscular and subcutaneous delivery, Oral forms cover capsules, liquid suspensions and syrups, and tablets, and Topical products are formulated as creams, lotions, and ointments; administration mode affects adherence, required caregiver skill, and product stability. Indication-based segmentation highlights focus areas such as chronic and acute pain management, immunological conditions, infectious diseases, metabolic and neurological disorders, orthopedic conditions, parasitic infections, and reproductive health, guiding clinical evidence generation and label claims. Distribution channels span online pharmacies, retail pharmacies, and veterinary clinics, each with different purchasing behaviors and regulatory obligations, while end users consist of animal farms, pet owners, and veterinary hospitals, informing pricing, packaging, and support services. Integrating these segmentation layers enables more precise targeting of R&D investments, commercialization plans, and post-market surveillance strategies.

Regional dynamics and regulatory nuances across the Americas, Europe Middle East Africa, and Asia-Pacific that determine access, adoption, and supply chain strategies

Regional dynamics shape regulatory frameworks, supply chain resilience, and commercial opportunity in distinct ways across geographies. In the Americas, market activity is driven by high adoption rates of advanced therapeutics in companion animals, progressive veterinary practice standards, and a robust network of retail and clinic-based distribution that accelerates uptake of novel formulations. Transactional behaviors and reimbursement nuances vary within the region, prompting manufacturers to adapt pricing strategies and to emphasize product safety and convenience for pet owners and large-scale farms alike.

Europe, the Middle East & Africa combine rigorous regulatory environments with diverse market maturities. Established European markets emphasize antimicrobial stewardship, stringent residue controls, and strong public sector engagement in livestock health, while markets in the Middle East and Africa present both growth opportunities and logistical complexities, including variability in cold-chain infrastructure and differing import regulations. Asia-Pacific is characterized by rapid modernization of livestock operations, intensifying demand for preventive vaccines and medicated feed solutions, and a growing companion animal segment with rising willingness to invest in advanced therapeutics. Supply chain considerations and local manufacturing partnerships play a pivotal role in all regions, and regulatory harmonization efforts, where they exist, materially influence market entry strategies and product lifecycle management.

Competitive differentiation through integrated R&D, manufacturing excellence, and strategic partnerships that accelerate biologics and advanced therapeutic commercialization

Competitive positioning in the sector reflects a mix of large multinational players, specialized biotechnology firms, and agile contract manufacturers. Leading companies differentiate through integrated capabilities that combine R&D strength, advanced manufacturing, and broad commercial networks, enabling rapid scale-up of biologics and complex formulations. Strategic alliances and licensing agreements are common as organizations seek to complement in-house expertise with niche technology providers, particularly in vaccine platform development and novel antiparasitic chemistries.

Innovation is increasingly financed through targeted partnerships, where larger firms provide capital and commercialization pathways while smaller entities supply scientific novelty. Companies that invest in digital tools for adherence monitoring, telehealth-enabled prescribing, and data-driven pharmacovigilance strengthen relationships with veterinarians and animal owners. Operational excellence in cold-chain logistics, regulatory affairs, and manufacturing quality is a persistent differentiator, as is the ability to demonstrate robust clinical evidence and stewardship frameworks. Overall, the competitive landscape rewards firms that combine scientific innovation with disciplined commercialization and supply chain resilience.

Practical strategic actions to align R&D focus, supply chain resilience, stewardship, and digital-enabled commercialization for sustainable competitive advantage

Industry leaders should align strategy with the twin imperatives of innovation and supply chain resilience to capture clinical and commercial value. Prioritize development programs that emphasize targeted therapeutics and preventative biologics, while embedding antimicrobial stewardship into labeling, marketing, and post-market surveillance activities to satisfy regulatory and societal expectations. Investing in formulation technologies that improve patient adherence, reduce dosing frequency, and simplify administration will drive uptake among clinicians and owners alike.

Simultaneously, reconfigure sourcing strategies to reduce tariff exposure and build redundancy through diversified supplier networks and regional manufacturing partnerships. Strengthen commercialization by integrating digital engagement platforms with traditional distribution channels to support telemedicine workflows, adherence monitoring, and data collection that bolster real-world evidence generation. Pursue collaborations and licensing models to accelerate access to novel platforms, while deploying rigorous pharmacovigilance and quality systems to maintain trust across stakeholders. Finally, tailor market entry plans to regional regulatory environments and species-specific needs to ensure alignment between clinical value propositions and local practice patterns.

Robust mixed-methods methodology combining primary stakeholder interviews, scientific literature review, regulatory analysis, and supply chain mapping to ensure actionable insights

The research methodology underpinning this analysis combined a multifaceted approach to ensure robustness, triangulating primary stakeholder insights with secondary scientific and regulatory literature. Primary engagements included structured interviews with veterinarians, industry executives, manufacturing partners, and distribution channel leaders to capture operational realities, unmet clinical needs, and procurement dynamics. These qualitative inputs were synthesized with public regulatory documents, peer-reviewed scientific studies, and corporate disclosures to validate therapeutic trends and to assess the practical implications of policy shifts.

Analytical steps included segmentation mapping across product types, species, administration routes, indications, distribution channels, and end users, enabling granular interpretation of where clinical demand aligns with commercial opportunity. Supply chain analysis focused on sourcing exposures, tariff impacts, and manufacturing capacity constraints. Finally, competitive assessment prioritized capabilities in R&D, manufacturing, regulatory affairs, and digital engagement. Throughout the methodology, care was taken to ensure transparency of assumptions and to corroborate findings through multiple independent sources, enhancing confidence in the conclusions and recommendations presented.

Conclusive synthesis emphasizing innovation alignment, stewardship integration, and supply chain redesign to translate scientific advances into durable commercial outcomes

In conclusion, the veterinary pharmaceuticals sector is navigating a period of substantive change driven by innovation in biologics and targeted therapeutics, evolving regulatory expectations, and commercial pressures stemming from trade adjustments and shifting distribution dynamics. These factors collectively require companies to be more strategic in product design, evidence generation, and supply chain configuration. Firms that proactively integrate stewardship principles, invest in formulating products that enhance compliance, and establish tariff-resilient sourcing will be better positioned to meet clinician and owner expectations while preserving operational margins.

The path forward involves a balanced approach: accelerate development of vaccines and targeted antiparasitics that reduce reliance on broad-spectrum antimicrobials, modernize manufacturing and logistics to mitigate trade-related disruptions, and adopt digital tools that enhance clinical decision-making and adherence. By aligning innovation priorities with regional regulatory nuances and end-user behaviors, organizations can translate scientific advances into durable commercial outcomes and improved animal health.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising regulatory restrictions driving development of non-antibiotic growth promoters in livestock feed
  • 5.2. Surge in telemedicine platforms integrating virtual consultations and e-prescribing for companion animal care
  • 5.3. Adoption of monoclonal antibody and novel biologics for targeted treatment of canine and feline diseases
  • 5.4. Expansion of advanced drug delivery systems such as sustained-release injectables in veterinary therapeutics
  • 5.5. Integration of wearable health monitoring technologies with pharmacotherapy to enhance treatment compliance
  • 5.6. Growing market for plant-derived nutraceuticals and functional pet foods for preventive veterinary health

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Veterinary Pharmaceuticals Market, by Products

  • 8.1. Drugs
    • 8.1.1. Analgesics
    • 8.1.2. Anti-Infectives
      • 8.1.2.1. Antibiotics
      • 8.1.2.2. Antifungals
    • 8.1.3. Anti-Inflammatories
      • 8.1.3.1. Non-Steroidal
      • 8.1.3.2. Steroidal
    • 8.1.4. Parasiticides
      • 8.1.4.1. Ectoparasiticides
      • 8.1.4.2. Endoparasiticides
  • 8.2. Medicinal Feed
    • 8.2.1. Antibiotic Medicated Feed
    • 8.2.2. Antiparasitic Medicated Feed
    • 8.2.3. Growth Promoters
    • 8.2.4. Nutritional Medicated Feed
    • 8.2.5. Probiotic & Prebiotic Medicated Feed
  • 8.3. Vaccines
    • 8.3.1. Inactivated Vaccines
    • 8.3.2. Live Vaccines

9. Veterinary Pharmaceuticals Market, by Animal Type

  • 9.1. Companion Animals
    • 9.1.1. Cats
    • 9.1.2. Dogs
    • 9.1.3. Horses
  • 9.2. Livestock Animals
    • 9.2.1. Cattle
    • 9.2.2. Poultry
    • 9.2.3. Sheep & Goats
    • 9.2.4. Swine

10. Veterinary Pharmaceuticals Market, by Mode of Administration

  • 10.1. Injectable
    • 10.1.1. Intramuscular
    • 10.1.2. Subcutaneous
  • 10.2. Oral
    • 10.2.1. Capsules
    • 10.2.2. Liquid Suspension & Syrup
    • 10.2.3. Tablets
  • 10.3. Topical
    • 10.3.1. Creams
    • 10.3.2. Lotions
    • 10.3.3. Ointments

11. Veterinary Pharmaceuticals Market, by Indications

  • 11.1. Chronic & Acute Pain Management
  • 11.2. Immunological Conditions
  • 11.3. Infectious Diseases
  • 11.4. Metabolic Disorders
  • 11.5. Neurological Disorders
  • 11.6. Orthopedic Disorders
  • 11.7. Parasitic Infections
  • 11.8. Reproductive Health

12. Veterinary Pharmaceuticals Market, by Distribution Channel

  • 12.1. Online Pharmacies
  • 12.2. Retail Pharmacies
  • 12.3. Veterinary Clinics

13. Veterinary Pharmaceuticals Market, by End User

  • 13.1. Animal Farms
  • 13.2. Pet Owners
  • 13.3. Veterinary Hospitals

14. Veterinary Pharmaceuticals Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Veterinary Pharmaceuticals Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Veterinary Pharmaceuticals Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Aurora Pharmaceutical, Inc.
    • 17.3.2. Biogenesis Bago S.A.
    • 17.3.3. Biovac Ltd.
    • 17.3.4. Boehringer Ingelheim International GmbH
    • 17.3.5. Ceva Sante Animale
    • 17.3.6. Chanelle Pharma
    • 17.3.7. China Animal Husbandry Industry Co., Ltd.
    • 17.3.8. Dechra Pharmaceuticals PLC
    • 17.3.9. ECO Animal Health Group PLC
    • 17.3.10. Elanco Animal Health Incorporated
    • 17.3.11. Heska Corporation
    • 17.3.12. Hester Biosciences Limited
    • 17.3.13. Indian Immunologicals Ltd.
    • 17.3.14. Intas Pharmaceuticals Ltd.
    • 17.3.15. Laboratorio Drag Pharma Chile Invetec S.A.
    • 17.3.16. Merck & Co., Inc.
    • 17.3.17. Neogen Corporation
    • 17.3.18. Norbrook Group
    • 17.3.19. Phibro Animal Health Corporation
    • 17.3.20. Teknofarma S.r.l.
    • 17.3.21. Vetoquinol Group
    • 17.3.22. Vetpharma Animal Health S.L. by Insud Pharma S.L.U.
    • 17.3.23. Virbac S.A.
    • 17.3.24. Zendal Group
    • 17.3.25. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PRODUCTS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PRODUCTS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INDICATIONS, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INDICATIONS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS VETERINARY PHARMACEUTICALS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE VETERINARY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST VETERINARY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA VETERINARY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC VETERINARY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN VETERINARY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC VETERINARY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION VETERINARY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS VETERINARY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 VETERINARY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO VETERINARY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. VETERINARY PHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. VETERINARY PHARMACEUTICALS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. VETERINARY PHARMACEUTICALS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DRUGS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANALGESICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANALGESICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANALGESICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANALGESICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANALGESICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFECTIVES, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFECTIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFECTIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFECTIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFECTIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFECTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFECTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORIES, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY NON-STEROIDAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY NON-STEROIDAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY NON-STEROIDAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY NON-STEROIDAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY NON-STEROIDAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY NON-STEROIDAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY STEROIDAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY STEROIDAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY STEROIDAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY STEROIDAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY STEROIDAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY STEROIDAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PARASITICIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ECTOPARASITICIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ECTOPARASITICIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ECTOPARASITICIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ECTOPARASITICIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ECTOPARASITICIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ECTOPARASITICIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ENDOPARASITICIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ENDOPARASITICIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ENDOPARASITICIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ENDOPARASITICIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ENDOPARASITICIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ENDOPARASITICIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY MEDICINAL FEED, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY MEDICINAL FEED, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY MEDICINAL FEED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY MEDICINAL FEED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY MEDICINAL FEED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY MEDICINAL FEED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY MEDICINAL FEED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY MEDICINAL FEED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTIC MEDICATED FEED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTIC MEDICATED FEED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTIC MEDICATED FEED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTIC MEDICATED FEED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTIC MEDICATED FEED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTIC MEDICATED FEED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIPARASITIC MEDICATED FEED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIPARASITIC MEDICATED FEED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIPARASITIC MEDICATED FEED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIPARASITIC MEDICATED FEED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIPARASITIC MEDICATED FEED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANTIPARASITIC MEDICATED FEED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY GROWTH PROMOTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY GROWTH PROMOTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY GROWTH PROMOTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY GROWTH PROMOTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY GROWTH PROMOTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY GROWTH PROMOTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY NUTRITIONAL MEDICATED FEED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY NUTRITIONAL MEDICATED FEED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY NUTRITIONAL MEDICATED FEED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY NUTRITIONAL MEDICATED FEED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY NUTRITIONAL MEDICATED FEED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY NUTRITIONAL MEDICATED FEED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PROBIOTIC & PREBIOTIC MEDICATED FEED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PROBIOTIC & PREBIOTIC MEDICATED FEED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PROBIOTIC & PREBIOTIC MEDICATED FEED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PROBIOTIC & PREBIOTIC MEDICATED FEED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PROBIOTIC & PREBIOTIC MEDICATED FEED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY PROBIOTIC & PREBIOTIC MEDICATED FEED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INACTIVATED VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INACTIVATED VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INACTIVATED VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INACTIVATED VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVE VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVE VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVE VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVE VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVE VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVE VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CATS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CATS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CATS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CATS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CATS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CATS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DOGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DOGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DOGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DOGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY DOGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY HORSES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY HORSES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY HORSES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY HORSES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY HORSES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY HORSES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIVESTOCK ANIMALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CATTLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CATTLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CATTLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CATTLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CATTLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY POULTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY POULTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY POULTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY POULTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY POULTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SHEEP & GOATS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SHEEP & GOATS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SHEEP & GOATS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SHEEP & GOATS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SHEEP & GOATS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SHEEP & GOATS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SWINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SWINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SWINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SWINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SWINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIQUID SUSPENSION & SYRUP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIQUID SUSPENSION & SYRUP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIQUID SUSPENSION & SYRUP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIQUID SUSPENSION & SYRUP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIQUID SUSPENSION & SYRUP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LIQUID SUSPENSION & SYRUP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CREAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CREAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CREAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CREAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CREAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LOTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LOTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LOTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LOTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LOTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY LOTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY OINTMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY OINTMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY OINTMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INDICATIONS, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CHRONIC & ACUTE PAIN MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CHRONIC & ACUTE PAIN MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CHRONIC & ACUTE PAIN MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CHRONIC & ACUTE PAIN MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CHRONIC & ACUTE PAIN MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY CHRONIC & ACUTE PAIN MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY IMMUNOLOGICAL CONDITIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY IMMUNOLOGICAL CONDITIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY IMMUNOLOGICAL CONDITIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY IMMUNOLOGICAL CONDITIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY IMMUNOLOGICAL CONDITIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY IMMUNOLOGICAL CONDITIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL VETERINARY PHARMACEUTICALS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-20